| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016NatCo...712335S |
| P6179 | Dimensions Publication ID | 1043247439 |
| P356 | DOI | 10.1038/NCOMMS12335 |
| P932 | PMC publication ID | 4979067 |
| P698 | PubMed publication ID | 27498556 |
| P50 | author | James P. Allison | Q6140731 |
| P2093 | author name string | Padmanee Sharma | |
| Sumit K Subudhi | |||
| Baoxiang Guan | |||
| Lewis Zhichang Shi | |||
| Jianjun Gao | |||
| Tihui Fu | |||
| Jianfeng Chen | |||
| Jorge M Blando | |||
| Liangwen Xiong | |||
| P2860 | cites work | Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death | Q24293504 |
| IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells | Q24546362 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro | Q39656364 | ||
| Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy | Q39707212 | ||
| The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder. | Q40591671 | ||
| Mouse CD1-specific NK1 T cells: development, specificity, and function | Q41464349 | ||
| Role of NK cells in tumour growth and metastasis in beige mice | Q41643296 | ||
| Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment | Q45875424 | ||
| Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade | Q46178232 | ||
| IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer | Q46230783 | ||
| Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies | Q47936492 | ||
| Induction of an IL7-R(+)c-Kit(hi) myelolymphoid progenitor critically dependent on IFN-gamma signaling during acute malaria | Q47940448 | ||
| IL-7 abrogates suppressive activity of human CD4+CD25+FOXP3+ regulatory T cells and allows expansion of alloreactive and autoreactive T cells. | Q50929763 | ||
| The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. | Q50940546 | ||
| Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. | Q52004225 | ||
| Differential In Vivo Persistence of Two Subsets of Memory Phenotype CD8 T Cells Defined by CD44 and CD122 Expression Levels | Q58581829 | ||
| Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor | Q72098225 | ||
| Use of statins and the risk of death in patients with prostate cancer | Q86645078 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| The future of immune checkpoint therapy | Q28259862 | ||
| Enhancement of antitumor immunity by CTLA-4 blockade | Q28275730 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 | Q29619280 | ||
| PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors | Q29619686 | ||
| IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity | Q29620119 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial | Q34058870 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate gene expression and production of interleukin-7 in human intestinal epithelial cells. | Q35126816 | ||
| Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo | Q35235365 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. | Q35617517 | ||
| Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma | Q35624496 | ||
| Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity | Q35870655 | ||
| Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. | Q36106006 | ||
| PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines | Q36334073 | ||
| Interleukin 7 regulates the survival and generation of memory CD4 cells | Q36371578 | ||
| Differential tumor surveillance by natural killer (NK) and NKT cells. | Q36375962 | ||
| Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent | Q36616920 | ||
| Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets | Q36742299 | ||
| Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. | Q36941194 | ||
| Inhibitory role of the transcription repressor Gfi1 in the generation of thymus-derived regulatory T cells. | Q37117826 | ||
| Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies | Q37125759 | ||
| Homeostasis of naive and memory T cells | Q37356053 | ||
| IL-7 receptor expression provides the potential for long-term survival of both CD62Lhigh central memory T cells and Th1 effector cells during Leishmania major infection | Q37367860 | ||
| Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). | Q37684283 | ||
| Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition | Q39085608 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 12335 | |
| P577 | publication date | 2016-08-08 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy | |
| P478 | volume | 7 |
| Q64085836 | A Bivalent Recombinant BCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4 T Cell Immune Response |
| Q92376089 | Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade |
| Q33875293 | Attenuation of Innate Immunity by Andrographolide Derivatives Through NF-κB Signaling Pathway. |
| Q41701099 | Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. |
| Q92992303 | Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner |
| Q60912825 | CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade |
| Q89964209 | Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis |
| Q42513019 | Genetic variation in IRF4 expression modulates growth characteristics, tyrosinase expression and interferon-gamma response in melanocytic cells. |
| Q89495011 | Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy |
| Q89158464 | IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy |
| Q50004232 | IL-2 and Beyond in Cancer Immunotherapy |
| Q47290509 | Informatics for cancer immunotherapy |
| Q89965765 | Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment |
| Q92441361 | Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma |
| Q92661775 | Local and Systemic IL-7 Concentration in Gastrointestinal-Tract Cancers |
| Q38743794 | Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy |
| Q64064468 | Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells |
| Q64107755 | Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? |
| Q89640748 | Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies |
| Q37716710 | ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line |
| Q90055145 | Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy |
| Q49715023 | Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. |
| Q34550649 | Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy |
| Q47678849 | The diverse functions of the PD1 inhibitory pathway |
| Q52720460 | The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. |
| Q38710357 | VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer |
Search more.